GlassScriptPhysician profile
Tangela C Atkinson
NPI 1659320786
$6,013.30
in general payments reported to CMS, 2019-2025
37 companies · $1,119 in 2025
The $1,119 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $724 · 2020: $252 · 2021: $1,086 · 2022: $817 · 2023: $868 · 2024: $1,147 · 2025: $1,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,133.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $877.31 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $726.88 | 2019-2025 | Evenity, Prolia, Repatha |
| Astellas Pharma US INC | $572.55 | 2019-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $428.67 | 2019-2025 | Jardiance |
| Pfizer INC. | $368.65 | 2019-2025 | |
| Abbvie INC. | $293.48 | 2019-2025 | Qulipta, Ubrelvy |
| Lilly USA, LLC | $285.63 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $224.36 | 2020-2025 | |
| Abbott Laboratories | $222.54 | 2019-2025 | Freestyle Libre 3, Proclaim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $207.24 | 2019-2024 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $189.21 | 2019-2024 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $168.84 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Dexcom, INC. | $158.83 | 2022-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $117.17 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $105.40 | 2019-2024 | Dificid, Gardasil 9, Capvaxive |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tangela Atkinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.